The India of forty years ago is not the same country we see today. The same goes for Sri Krishna Pharmaceuticals. Both country and company have evolved to become dynamic growth driven entities.
Sri Krishna enters this new decade firm in the belief that demand for our products will be far reaching. Further development in finished dosage and formulation will keep in touch with API diversity.
• All units integrated under one name: Sri Krishna Pharmaceuticals Limited
• USFDA, TGA and WHO GMP inspections at Unit I for Acetaminophen (Paracetamol) and Domperidone / Domperidone Maleate
• Renewed Unit II GMP compliance certificates received from German, Brazilian (ANVISA) and Mexican (COFEPRIS) regulatory authorities
• Unit II gains Italian (AIFA) approval for all solid dosage formats
• Unit III receives surveillance inspection and certification by USFDA for Folic Acid manufacturing
• USFDA inspection and TGA, AFSSAPS, WHO GMP approval for Acetaminophen (Paracetamol)
• AIFA, AFSSAPS, WHO GMP approval for Domperidone/ Domperidone Maleate
• Formulation manufacturing started, and direct compression granules roll out at Unit II
• Unit II receives TGA, AIFA GMP and ISO 9001:2008 (AQA) IN 013630 QMS compliance certification and USFDA compliance for GMP of Acetaminophen Granules DC 90%
• Acquisition of Arandy Labs in Bollaram, Hyderabad (Unit IV) – providing a niche API manufacturing facility and range of anti-diabetic products
• Solapur manufacturing facility (Unit V) established for custom synthesized intermediates
• Unit I upgraded with a focus on compliance with GMP practices
• Second facility at Nacharam (Unit II) established as a direct compression facility
• Third facility set up as Sri Krishna Drugs at Shamshabad (Unit III)
• Sri Krishna Drugs becomes the first private sector company in India to manufacture folic acid
• Sri Krishna Pharmaceuticals established in 1974 by Dr. V V Subba Reddy at Uppal, Hyderabad (Unit I)
• Production goes live for Acetaminophen (Paracetamol) at the Uppal facility